Short answer
Revvity (RVTY) filed its fiscal 2025 10-K annual report with the SEC on Feb 24, 2026. It reported revenue of $2.9B (+3.7% year over year) and net income of $241M.
- Top risk flagged: Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S.
FY2025 key financial metrics · XBRL
- Revenue
- $2.9B
- +3.7% YoY
- Net income
- $241M
- −10.8% YoY
- Operating margin
- 12.5%
- −0.1 pp YoY
- EPS (diluted)
- $2.07
- −5.9% YoY
- ROE
- 3.3%
- −0.2 pp YoY
- Operating cash flow
- $583M
- −7.2% YoY
Source: XBRL data from the Revvity (RVTY) FY2025 10-K on SEC EDGAR. USD.
Revvity FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Health science solutions provider across two segments (Life Sciences and Diagnostics), serving drug discovery through clinical diagnostics in 160+ countries
- Notable new products in FY2025: Phenologic.AI™ deep-learning imaging module, EnVision Nexus® plate reader, NeoLSD™ 7 Plex MS/MS kit (first IVD for 7 lysosomal disorders from single blood spot), and T-SPOT.Flex™ customizable ELISPOT kit
- AI integration accelerated across portfolio: Pin-point® base editing expanded with Profluent AI-enhanced adenine deaminase editors; EUROPattern™ Classifier 2.4 AI-enhanced IFA software; Living Image™ Synergy AI multimodal imaging platform
- ~11,000 employees globally as of Dec 28, 2025; ~80% based outside the US; ~4,000 covered by labor union/works council agreements
- Great Place to Work certifications achieved across India, China, Poland, US, and Brazil (Euroimmun) in 2025, with improved US scores YoY: notable cultural milestone for a company mid-transformation from PerkinElmer rebrand
Management Discussion & Analysis
- Revenue $2,856.1M in FY2025, up $101.1M (+4%) YoY; Diagnostics +5% ($68.5M), Life Sciences +2% ($32.5M)
- Gross margin 54.8% vs 55.8%; operating margin decreased 10 bps; SG&A ratio 34.7% vs 36.1%
- Best segment: Diagnostics revenue +5% to $1,424.9M; worst: Life Sciences margin 32.0% vs 33.4% (-139 bps), Diagnostics margin 24.2% vs 26.1% (-194 bps)
- Operating cash flow $589.0M vs $665.0M; buybacks $820.8M; capex $73.5M; dividends $32.8M
- Key risks: tariff impact ~$20M net on gross margin; Life Sciences Solutions goodwill ($4.5B) fair value only 10–20% above carrying value; capex planned higher in FY2026
Risk Factors
- Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S.
- U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments
- Single/limited-source suppliers for critical raw materials with multi-year contracts carrying no minimum purchase requirements, creating supply disruption risk
- $9.0B net intangible assets on balance sheet as of December 28, 2025: impairment risk if Life Sciences or Diagnostics segments underperform
- Substantial debt across multiple tranches (2026–2051 Notes) with covenants restricting dividends, asset sales, and M&A; loss of investment-grade rating triggers higher costs
Generated from the filing text; verify against the original. How to read a 10-K
Other Revvity annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.